Vicky B. Gregg, a director at Quest Diagnostics Inc. (NYSE: DGX), acquired 72 shares of common stock on July 22, 2026, through a dividend reinvestment plan administered by her broker. The transaction, reported on July 27, 2026, brings Gregg's total beneficial ownership to 18,386 shares. The acquisition occurred at a price of $206.808 per share and reflects automatic dividend reinvestment activity at the diagnostic testing company.
Key Points
- NYSE: DGX
- Director Vicky B. Gregg acquired 72 shares on July 22, 2026, through a dividend reinvestment plan
- Share purchase price was $206.808 per share; total beneficial ownership increased to 18,386 shares
- The transaction represents automatic dividend reinvestment eligible for deferred reporting, though the director chose early reporting on this disclosure
Director Share Acquisition Through Dividend Reinvestment Program
Vicky B. Gregg, identified in the disclosure as a director of Quest Diagnostics, executed a share acquisition on July 22, 2026. The purchase involved 72 shares of common stock at a per-share price of $206.808. According to the filing, these shares were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker, a mechanism that automatically reinvests dividend payments into additional shares of the issuer's stock.
The disclosure indicates that these shares were eligible for deferred reporting under Rule 16a-6 on Form 5; however, Gregg chose to report the transaction early by filing on Form 4. This voluntary early reporting provides investors with more timely information regarding changes in insider beneficial ownership at the diagnostics company. The filing was executed on July 27, 2026, five days after the transaction date.
Beneficial Ownership Position Following the Transaction
Following the acquisition of the 72 shares, Gregg's total beneficial ownership of Quest Diagnostics common stock stands at 18,386 shares, held in direct ownership form. This ownership position reflects her accumulated equity stake in the company as a member of its board of directors. The disclosure provides investors with a current snapshot of her financial interest in the diagnostic testing and information services provider.
The beneficial ownership figure represents Gregg's direct holdings in the company and does not account for any derivative securities or indirect ownership arrangements that may exist. Investors monitoring insider ownership patterns often track such changes as indicators of director confidence in the company's direction and financial performance, though acquisition through automatic dividend reinvestment may reflect routine capital management rather than discretionary trading activity.
Nature of the Dividend Reinvestment Transaction
Dividend reinvestment plans (DRIPs) are structured programs that automatically use cash dividend payments to purchase additional shares of a company's stock rather than distributing them to shareholders as cash. For insiders such as board members and executives, DRIPs represent a passive investment mechanism that accumulates equity ownership over time without requiring active trading decisions. In this instance, Gregg's broker administered the reinvestment of her Quest Diagnostics dividend, resulting in the acquisition of 72 additional shares.
The filing reflects that the reporting person's broker managed the transaction, meaning the shares were acquired on Gregg's behalf through the automated plan. This type of transaction is commonly viewed as routine wealth accumulation activity by insiders who maintain long-term holdings in their employer company. The decision to report the transaction early rather than defer it to Form 5 demonstrates proactive disclosure compliance by the director.
Regulatory Filing Context and Insider Reporting Requirements
The disclosure was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and beneficial owners of more than 10 percent of a company's equity securities to report changes in their beneficial ownership. Vicky B. Gregg's status as a director subjects her to these reporting obligations, and her timely filing on July 27, 2026, fulfills the regulatory requirement to disclose her securities transactions.
Form 4 filings must be submitted within two business days of the transaction date, a requirement designed to ensure that material insider ownership changes reach investors promptly. The disclosure identifies Sean D. Mersten as the attorney in fact for Gregg, indicating that the filing was executed on her behalf by an authorized legal representative. This type of delegation is common practice for managing the administrative aspects of insider reporting compliance.
Quest Diagnostics Insider Ownership Monitoring
Investors tracking insider activity at Quest Diagnostics may monitor Form 4 filings to assess the investment patterns of company leadership, including board members such as Gregg. Dividend reinvestment activity generally suggests that insiders are maintaining confidence in the company and choosing to increase their ownership stakes through capital accumulation rather than selling shares. However, such passive acquisitions through DRIPs may carry different analytical weight than active open-market purchases initiated by company insiders.
The cumulative effect of dividend reinvestment over time can substantially increase an insider's beneficial ownership position, particularly for long-tenured board members or executives. Gregg's current beneficial ownership of 18,386 shares reflects the accumulated result of both prior acquisitions and ongoing dividend reinvestment activity at the diagnostic testing company. Investors comparing insider ownership levels across different time periods should account for both active trading and passive reinvestment contributions to overall beneficial ownership changes.
Price Per Share Context at Transaction Date
The shares were acquired at a price of $206.808 per share on July 22, 2026. This price represents the transaction value used for calculating dividend reinvestment plan activity on the specific date, determined by the plan administration mechanics and the company's dividend payment methodology. The filing provides investors with the exact price at which dividend proceeds were converted into additional share ownership on that transaction date.
Understanding the transaction price can provide context for analyzing Gregg's cost basis and the accumulated value of her beneficial ownership position. However, the transaction price for dividend reinvestment plans is mechanically determined rather than discretionary, as it reflects the market value at the time dividend payments were processed through the broker-administered plan. This contrasts with open-market purchases where insiders actively choose both timing and price execution.
Direct Ownership Structure and Future Disclosure Obligations
The disclosure indicates that Gregg holds all 18,386 shares in direct ownership form, meaning they are registered directly in her name or held in a brokerage account under her direct control. Direct ownership is distinguished from indirect beneficial ownership, which may occur through trusts, family relationships, partnerships, or other arrangements where beneficial interest exists but legal title may be held differently. The filing confirms that no indirect ownership arrangements are involved in this particular shareholding at Quest Diagnostics.
As a director subject to Section 16 reporting obligations, Gregg will continue to file Form 4 disclosures whenever her beneficial ownership changes through future transactions, whether those transactions result from active trading, equity compensation, or dividend reinvestment activity. The ongoing nature of insider reporting requirements ensures that investors receive regular updates regarding changes in Quest Diagnostics board member equity interests, contributing to transparency regarding leadership investment alignment with shareholder interests.
Investor Considerations for Insider Ownership Analysis
When analyzing insider ownership disclosures such as this Form 4 filing, investors should distinguish between different types of insider transactions and ownership changes. Dividend reinvestment represents passive capital accumulation, while open-market purchases or sales reflect more deliberate trading decisions that may carry stronger signals regarding insider views of company valuation and prospects. The filing itself does not provide commentary on Gregg's investment outlook, market timing rationale, or confidence level in Quest Diagnostics' future performance.
The aggregate beneficial ownership position of 18,386 shares, while material to Gregg personally, represents a minority stake relative to the total equity capitalization of Quest Diagnostics as a major public company. Monitoring individual insider ownership levels gains greater analytical significance when reviewing collective insider activity across multiple company leaders or when tracking substantial changes in individual insider positions over time. Investors should review the company's periodic proxy filings and beneficial ownership disclosures for comprehensive context regarding overall insider participation and alignment at the diagnostic testing firm.




Please wait processing your request...